Abstract
Conjunctival malignant melanoma is a pigmented lesion of the ocular surface. It is an uncommon but potentially devastating tumor that may invade the local tissues of the eye, spread systemically through lymphatic drainage and hematogenous spread, and recur in spite of treatment. Despite its severity, the rarity of available cases has limited the evidence for diagnosis and management. This review will provide an overview of the epidemiology, risk factors, presentation, diagnosis, management, prognosis, staging, and surveillance of conjunctival melanoma, with an emphasis on recent advances in biological therapies to treat this disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 185-204 |
| Number of pages | 20 |
| Journal | Expert Review of Ophthalmology |
| Volume | 9 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 2014 |
Keywords
- BRAF inhibitors
- Conjunctival malignant melanoma
- Dabrafenib
- IFNa-2b
- Ipilimumab
- Melanoma mitomycin C
- Ocular neoplasm
- Vemurafenib
ASJC Scopus subject areas
- Ophthalmology
- Biomedical Engineering
- Optometry
Fingerprint Dive into the research topics of 'Management of conjunctival malignant melanoma: A review and update'. Together they form a unique fingerprint.
Cite this
Wong, J. R., Nanji, A. A., Galor, A., & Karp, C. L. (2014). Management of conjunctival malignant melanoma: A review and update. Expert Review of Ophthalmology, 9(3), 185-204. https://doi.org/10.1586/17469899.2014.921119